---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical presentation - signs and symptoms. Topics: Cutaneous swelling: hands, feet, and face; Gastrointestinal symptoms: intestinal attacks; Airway symptoms: obstruction risk; Distribution of attacks by site: edema episodes reported by 221 patients; 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Cutaneous swelling: hands, feet, and face

> “HAE is a very rare and potentially life-threatening genetic condition involving swelling of various parts of the body, hands, feet, or face.”

Source: [US Hereditary Angioedema Association](https://www.haea.org/)

<a id="topic-2.2.1.6-2"></a>

### Gastrointestinal symptoms: intestinal attacks

> “severe abdominal pain, nausea, and vomiting.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.6-3"></a>

### Airway symptoms: obstruction risk

> “can restrict breathing and lead to life-threatening obstruction of the airway.”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.6-4"></a>

### Distribution of attacks by site: edema episodes reported by 221 patients

> “Skin swellings, including extremity, facial, genital, and trunk swellings, and abdominal attacks occurred in 97.4% of all edema episodes of the disease.”
> “The other episodes were laryngeal edema (0.9%); edema of the soft palate (0.6%); tongue swellings (0.3%); headache episodes (0.7%); episodes affecting urinary bladder (0.3%), chest (0.2%), muscles (0.4%), joints (0.1%), kidneys (0.1%), and esophagus (0.05%), and were partly combined with other edema episodes.”

Source: [Bork et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16490473/)

<a id="topic-2.2.1.6-5"></a>

### Abdominal and laryngeal involvement: proportion of patients affected

> “Abdominal involvement occurs in 70%–90% of all individuals and is associated with high morbidity.”
> “Laryngeal involvement, although accounting for less than 1% of all attacks, poses a risk of death and occurs at least once in about half of patients.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.6-6"></a>

### Airway symptoms: phases of fatal laryngeal attacks

> “Phase 1, the predyspnea phase, lasted on average for 3.7 ± 3.2 hours (range, 0-11 hours).”
> “Phase 2, the dyspnea phase, lasted on average for 41 ± 49 minutes (range, 2 minutes to 4 hours).”

Source: [Bork et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22841766/)

<a id="topic-2.2.1.6-7"></a>

### Prodromal symptoms and erythema marginatum

> “Non-specific prodromal symptoms are common and can include anxiety, nausea, paresthesia, and fatigue.”
> “One third of patients with HAE, especially children, experience erythema marginatum (a nonpruritic form of flat, figurate erythema) as an initial manifestation, which may mimic the skin lesions of urticaria.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
